ATE506955T1 - Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin - Google Patents
Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatinInfo
- Publication number
- ATE506955T1 ATE506955T1 AT05813305T AT05813305T ATE506955T1 AT E506955 T1 ATE506955 T1 AT E506955T1 AT 05813305 T AT05813305 T AT 05813305T AT 05813305 T AT05813305 T AT 05813305T AT E506955 T1 ATE506955 T1 AT E506955T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- adverse gastrointestinal
- pharmaceutical
- carbohydrate
- drug
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 190000008236 CARBOPLATIN Chemical compound 0.000 title 1
- 229960004562 carboplatin Drugs 0.000 title 1
- 229960004316 cisplatin Drugs 0.000 title 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title 1
- 229960001756 oxaliplatin Drugs 0.000 title 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 230000002496 gastric effect Effects 0.000 abstract 4
- 230000002411 adverse Effects 0.000 abstract 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 2
- 239000003613 bile acid Substances 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61919904P | 2004-10-15 | 2004-10-15 | |
| PCT/US2005/037211 WO2006044771A2 (en) | 2004-10-15 | 2005-10-14 | Methods and compositions for reducing toxicity of a pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE506955T1 true ATE506955T1 (de) | 2011-05-15 |
Family
ID=36203610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05813305T ATE506955T1 (de) | 2004-10-15 | 2005-10-14 | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7932243B2 (de) |
| EP (1) | EP1809330B1 (de) |
| JP (1) | JP2008516977A (de) |
| KR (1) | KR20070084211A (de) |
| CN (1) | CN101039699B (de) |
| AT (1) | ATE506955T1 (de) |
| AU (1) | AU2005295541B2 (de) |
| BR (1) | BRPI0518191A (de) |
| CA (1) | CA2584184A1 (de) |
| DE (1) | DE602005027727D1 (de) |
| WO (1) | WO2006044771A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| CA2577268A1 (en) * | 2004-08-30 | 2006-03-09 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| ATE506955T1 (de) | 2004-10-15 | 2011-05-15 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| WO2006050165A2 (en) * | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| BRPI0709410A2 (pt) * | 2006-03-20 | 2011-07-12 | Javelin Pharmaceuticals Inc | composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético |
| KR20150050595A (ko) * | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| JP2010503667A (ja) * | 2006-09-15 | 2010-02-04 | ホン ユー，ソ | 大腸疾患用胆汁製剤 |
| WO2009148315A1 (en) * | 2008-06-06 | 2009-12-10 | N.V. Nutricia | Method for preventing corticosteroid usage |
| CZ302789B6 (cs) * | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
| PL2616064T3 (pl) | 2010-10-21 | 2020-02-28 | Rtu Pharmaceuticals Llc | Gotowe do zastosowania formulacje ketorolaku |
| US10369108B2 (en) | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| AU2015256331B2 (en) * | 2014-05-09 | 2020-03-12 | AuroMedics Pharma LLC | Formulations of Cyclophosphamide liquid concentrate |
| US10729700B2 (en) | 2014-06-27 | 2020-08-04 | Medytox Inc. | Methods and compositions of bile acids and salts for reduction of fat |
| KR102204406B1 (ko) * | 2019-01-23 | 2021-01-18 | (주)샤페론 | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물 |
| US20230091702A1 (en) * | 2019-11-01 | 2023-03-23 | Peking University | Use of bile acids and derivatives thereof in preparation of gpr39 agonist |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2148890A5 (de) * | 1971-08-09 | 1973-03-23 | Peugeot & Renault | |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4092428A (en) | 1973-11-02 | 1978-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | Process of preparing stable prostaglandin E group-containing formulation |
| US4036954A (en) | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
| US4113882A (en) | 1974-10-21 | 1978-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Stabilized oral prostaglandin formulation and the process for the preparation thereof |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| JPS5522616A (en) | 1978-08-04 | 1980-02-18 | Tokyo Tanabe Co Ltd | Bile acid inclusion compound and injection containing the same |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| FR2521430A1 (fr) | 1982-02-12 | 1983-08-19 | Pan Medica | Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires |
| GB8313217D0 (en) | 1983-05-13 | 1983-06-22 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB8417895D0 (en) | 1984-07-13 | 1984-08-15 | Marples B A | Pharmaceutical anti-fungal composition |
| JPS61171421A (ja) | 1985-08-23 | 1986-08-02 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンｅ類製剤の製造方法 |
| JPS62153220A (ja) | 1985-12-27 | 1987-07-08 | Tokyo Tanabe Co Ltd | 胆汁酸内用水剤 |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| JPH0747539B2 (ja) | 1986-10-22 | 1995-05-24 | 東京田辺製薬株式会社 | 胆汁酸固形製剤 |
| JPS63243031A (ja) | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | 胆汁酸の固形製剤 |
| HU203204B (en) | 1987-09-15 | 1991-06-28 | Sandoz Ag | Process for producing suppository containing calcitonin and taurocholic acid |
| JP2851627B2 (ja) | 1987-10-15 | 1999-01-27 | シンテックス（ユー・エス・エイ）インコーポレイテッド | 粉末形態ポリプペチド類の経鼻投与 |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| US5446026A (en) | 1989-08-09 | 1995-08-29 | Advanced Peptides & Biotechnology Sciences | Potent non-opiate analgesic |
| US5157022A (en) | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
| WO1991015548A1 (en) | 1990-04-04 | 1991-10-17 | Berwind Pharmaceutical Services, Inc. | Aqueous maltodextrin and cellulosic polymer film coatings |
| US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
| IT1245889B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari. |
| IT1245890B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| IT1245891B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
| CH680704A5 (de) | 1991-05-15 | 1992-10-30 | Medichemie Ag | |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| HU209251B (en) | 1992-03-13 | 1994-04-28 | Synepos Ag | Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons |
| US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| US5342934A (en) | 1992-06-19 | 1994-08-30 | The Trustees Of Columbia University In The City Of New York | Enantioselective receptor for amino acid derivatives, and other compounds |
| US5260074A (en) | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5578304A (en) | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5302400A (en) | 1992-06-22 | 1994-04-12 | Digestive Care Inc. | Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| IT1255968B (it) | 1992-11-27 | 1995-11-17 | Composizioni farmaceutiche contenenti acido ursodesossicolico | |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| CA2159219A1 (en) | 1993-03-31 | 1994-10-13 | Minoru Maeda | Cholestasis ameliorant |
| LU88375A1 (fr) | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Produit énergétique stimulant la puissance virile |
| WO1995003056A1 (en) | 1993-07-19 | 1995-02-02 | Tokyo Tanabe Company Limited | Hepatitis c virus proliferation inhibitor |
| DK0640344T3 (da) | 1993-08-30 | 1999-07-05 | Medichemie Ag | Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform |
| GB9405833D0 (en) | 1994-03-24 | 1994-05-11 | Pfizer Ltd | Separation of the enantiomers of amlodipine |
| DE4432708A1 (de) | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
| US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5686588A (en) | 1995-08-16 | 1997-11-11 | Yoo; Seo Hong | Amine acid salt compounds and process for the production thereof |
| WO1997034608A1 (en) | 1996-03-22 | 1997-09-25 | Mayo Foundation For Medical Education And Research | Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| US6596712B2 (en) * | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US5750104A (en) | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
| US5898028A (en) | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| DE29717252U1 (de) | 1997-09-26 | 1998-02-19 | Dr. Falk Pharma GmbH, 79108 Freiburg | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| AU3735899A (en) | 1998-05-28 | 1999-12-13 | Mediplex Corporation, Korea | Amphiphilic polysaccharide derivatives |
| KR100314496B1 (ko) | 1998-05-28 | 2001-11-22 | 윤동진 | 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도 |
| US6407117B1 (en) | 1998-06-18 | 2002-06-18 | The George Washington University | Method of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| RU2224523C2 (ru) | 1998-07-24 | 2004-02-27 | Сео Хонг Ю | Водный раствор, содержащий желчную кислоту, и способ его получения |
| US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US7303768B2 (en) | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US20050158408A1 (en) | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| AU785017B2 (en) | 2000-01-10 | 2006-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| AU3668501A (en) * | 2000-02-04 | 2001-08-14 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| EP1301091A2 (de) | 2000-07-18 | 2003-04-16 | The NutraSweet Company | Trocknung von neotame mit hilfsmitteln |
| US20030044413A1 (en) | 2000-08-15 | 2003-03-06 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| KR100368936B1 (ko) * | 2000-10-04 | 2003-01-24 | 주식회사 대웅 | 우루소데옥시콜린산을 함유한 환경호르몬 독성의 예방 및치료제 |
| AU2003261424A1 (en) | 2002-08-06 | 2004-02-23 | Nitromed, Inc. | Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use |
| ATE451108T1 (de) | 2002-11-07 | 2009-12-15 | Univ Minnesota | Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung |
| WO2004096123A2 (en) | 2003-04-02 | 2004-11-11 | Regents Of The University Of Minnesota | Methods of promoting cell viability |
| CA2577268A1 (en) * | 2004-08-30 | 2006-03-09 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| ATE506955T1 (de) | 2004-10-15 | 2011-05-15 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| WO2006050165A2 (en) * | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| JP2008521800A (ja) * | 2004-11-24 | 2008-06-26 | セオ ホン ユー | 水可溶化胆汁酸投薬処方の乾燥形態、その製造方法及び用途 |
-
2005
- 2005-10-14 AT AT05813305T patent/ATE506955T1/de not_active IP Right Cessation
- 2005-10-14 JP JP2007536987A patent/JP2008516977A/ja active Pending
- 2005-10-14 EP EP05813305A patent/EP1809330B1/de not_active Expired - Lifetime
- 2005-10-14 BR BRPI0518191-7A patent/BRPI0518191A/pt not_active IP Right Cessation
- 2005-10-14 WO PCT/US2005/037211 patent/WO2006044771A2/en not_active Ceased
- 2005-10-14 CA CA002584184A patent/CA2584184A1/en not_active Abandoned
- 2005-10-14 KR KR1020077010964A patent/KR20070084211A/ko not_active Ceased
- 2005-10-14 CN CN2005800348841A patent/CN101039699B/zh not_active Expired - Fee Related
- 2005-10-14 DE DE602005027727T patent/DE602005027727D1/de not_active Expired - Lifetime
- 2005-10-14 AU AU2005295541A patent/AU2005295541B2/en not_active Ceased
-
2006
- 2006-03-10 US US11/373,554 patent/US7932243B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008516977A (ja) | 2008-05-22 |
| US7932243B2 (en) | 2011-04-26 |
| KR20070084211A (ko) | 2007-08-24 |
| US20060188530A1 (en) | 2006-08-24 |
| CN101039699A (zh) | 2007-09-19 |
| WO2006044771A3 (en) | 2007-03-29 |
| CN101039699B (zh) | 2011-07-27 |
| WO2006044771A2 (en) | 2006-04-27 |
| CA2584184A1 (en) | 2006-04-27 |
| EP1809330B1 (de) | 2011-04-27 |
| EP1809330A2 (de) | 2007-07-25 |
| BRPI0518191A (pt) | 2008-11-04 |
| DE602005027727D1 (de) | 2011-06-09 |
| AU2005295541A1 (en) | 2006-04-27 |
| AU2005295541B2 (en) | 2011-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE506955T1 (de) | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin | |
| CR20210458A (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| EP1951729A4 (de) | Sauerstoffgebundene pyrimidinderivate | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
| EP2481409A3 (de) | Nanopartikel mit Rapamycin und Albumin als Antikrebsmittel | |
| WO2007044062A8 (en) | Bile preparations for gastrointestinal disorders | |
| MY155695A (en) | Quinoxalinedione derivatives | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| WO2006102610A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| JO2852B1 (en) | Anti-cancer compounds and pharmaceutical compositions | |
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| ATE468121T1 (de) | Zusammensetzungen zur verringerung des blutglukosespiegels und zur behandlung von diabetes | |
| MX2010004089A (es) | Compuestos metalicos mezclados para el tratamiento de hiperfosfatemia. | |
| PT2576524T (pt) | Resumo | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BRPI0514766A (pt) | composições farmacêuticas | |
| BRPI0513278A (pt) | uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton | |
| TW200727903A (en) | Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate | |
| BRPI0607703A2 (pt) | compostos de isoquinolina e métodos de uso dos mesmos | |
| ATE482922T1 (de) | Aloe-emodinderivate und deren verwendung in der behandlung von neoplasien | |
| IL186058A0 (en) | Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt | |
| BR112022009784A2 (pt) | Composições injetáveis de ácido ursodesoxicólico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |